Relmada Therapeutics (RLMD) Cash from Investing Activities (2014 - 2026)

Relmada Therapeutics (RLMD) has 13 years of Cash from Investing Activities data on file, last reported at -$135.2 million in Q1 2026.

• On a quarterly basis, Cash from Investing Activities fell 980.4% year-over-year to -$135.2 million in Q1 2026; TTM through Mar 2026 was -$198.7 million, a 449.48% decrease from a year earlier, with the FY2025 full-year figure at -$48.1 million, down 193.36% from the prior year.
• Cash from Investing Activities for Q1 2026 stood at -$135.2 million, down from -$76.9 million in the prior quarter.
• Over the last five years, Cash from Investing Activities for RLMD reached as high as $40.0 million in Q1 2023 and fell as low as -$135.2 million in Q1 2026.
• Historically, Cash from Investing Activities has averaged -$3.6 million across 5 years, with a median of $6.8 million in 2025.
• Across the five-year window, Cash from Investing Activities soared 1316.79% in 2024 and plunged 980.4% in 2026, its largest moves.
• Year by year, Cash from Investing Activities stood at -$1.7 million in 2022, then jumped by 567.62% to $7.7 million in 2023, then soared by 46.56% to $11.3 million in 2024, then slumped by 778.07% to -$76.9 million in 2025, then sank by 75.78% to -$135.2 million in 2026.
• Per Business Quant data, the three most recent Cash from Investing Activities figures were -$135.2 million in Q1 2026, -$76.9 million in Q4 2025, and $6.8 million in Q3 2025.